RxDoctor Payments Data

Michael Heise, MD

Internal Medicine · Mc Murray, PANPI 1003804162

Payments from drug & device makers

$3,861in general payments, 2019–2025

Across 208 payments — averaging $18.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$1K
  • Novo Nordisk$496
  • AbbVie$417
  • Pfizer$399
  • Amgen$197
  • Abbott$175
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,861100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,861 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$91,123
Medicare patients
164
Services billed
815

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban327$170,552
OzempicSemaglutide68$75,182
XareltoRivaroxaban102$56,250
JanuviaSitagliptin Phosphate44$48,104
MounjaroTirzepatide31$46,818
JardianceEmpagliflozin81$43,022
NuplazidPimavanserin Tartrate15$36,748
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$35,999
TrulicityDulaglutide21$26,279
Breo ElliptaFluticasone/Vilanterol32$18,410
VeltassaPatiromer Calcium Sorbitex14$14,010
FarxigaDapagliflozin Propanediol21$11,215
RestasisCyclosporine13$8,753
EntrestoSacubitril/Valsartan12$7,860
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$7,407

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$399$173,436339 claims
Novo NordiskOzempic$496$75,18268 claims
Lilly USA, LLCMounjaro, Trulicity$124$73,09852 claims
Johnson & JohnsonXarelto$25$56,250102 claims
GSKTrelegy Ellipta, Breo Ellipta$147$54,40984 claims
Acadia Pharmaceuticals IncNuplazid$47$36,74815 claims
AbbVieRestasis, Namzaric, Synthroid$417$18,908122 claims
Astellas Pharma US IncMyrbetriq$39$5,71612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Mc Murray

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →